Answers are grounded in this paper and cite their sources.
This article summarizes the challenge of developing pediatric therapies to slow myopia, suggesting clinical pharmacology can optimize this process.
Myopia (nearsightedness) is in epidemic proportions in the world today. The eyecare community has long been desirous of pharmacological treatments to slow myopic progression. Most recently, two proprietary formulations of low-dose atropine were approved. In this article, the author summarizes the challenge to develop therapies for a chronic, preventative, and pediatric treatment, and how clinical pharmacologists' knowledge of pharmaceutics, pharmacokinetics, and therapeutics can optimize the development of therapies to slow myopic progression.
No takes yet. Share an insight, caveat, or question.
Gary D. Novack (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: